Prescribing guide
Soliris (eculizumab)Meningococcal vaccine requirements, REMS, loading and maintenance dosing, plasma exchange supplements and prior authorization for NMOSDFor prescribers and their offices treating neuromyelitis optica spectrum disorder (NMOSD): what the pharmacy needs before it ships, what the prior authorization wants documented, the titration and the monitoring the label requires.
Dispensing gate
REMS-certified prescriber, MenACWY and MenB vaccination completed or updated at least 2 weeks before day 1 or antibacterial prophylaxis with vaccines as soon as possible, counseling with the Patient Safety Card and Patient Guide, and a REMS-certified healthcare setting or pharmacy that verifies prescriber certification before each dispense.
Example PA threshold
Label: adults with NMOSD who are anti-AQP4 antibody positive. Aetna CPB 0807 example, November 2026: AQP4 positive, one core clinical characteristic, no other NMOSD biologic, neurologist. Label trial: 2 relapses in 12 months or 3 in 24 months with 1 in the prior 12, EDSS 7 or lower.
Monitoring
Meningococcal infection at any time, at least 1 hour of observation after each infusion, revaccination per ACIP for the duration of therapy; no scheduled laboratory test is written into the label for NMOSD.
Support line
Alexion OneSource, 1-888-765-4747, Monday to Friday 8:30 AM to 8 PM ET, insurance navigation, vaccination support, CoPay Program as little as $0 for commercial plans, enrollment fax 1-800-420-5150; the label lists the same number for the REMS.
Give your patient their plan
A one-page handout for starting Soliris, in plain language: what the first fill waits on, the first dates, who will call and the symptoms to report, with blank lines for the start date and your office's number. The link opens the patient's full first 90 days page, where their dates become calendar entries.
trialfriend.com/p/solirisBefore the first fill: REMS, labs and enrollment
The steps that the pharmacy, the REMS or the drugmaker's program will wait on, in the order they usually need to happen. A first fill of a specialty drug most often stalls on one of these rather than on the plan.
| Step | What it requires | Source |
|---|---|---|
| Confirm the indication | NMOSD in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. Safety and effectiveness in pediatric patients with NMOSD have not been established. | FDA label |
| Certify in the ULTOMIRIS and SOLIRIS REMS | Review the Prescribing Information, Healthcare Provider Safety Brochure, Patient Safety Card and Patient Guide, then submit the Prescriber Enrollment Form. Counsel with the card and guide and give the patient copies. REMS line 1-888-765-4747, www.UltSolREMS.com per the label. | FDA REMS page |
| Vaccinate | Complete or update vaccination against Neisseria meningitidis serogroups A, C, W, Y and B at least 2 weeks before the first dose, per current ACIP recommendations for complement inhibitor recipients. ACIP's schedule for these patients differs from the vaccine prescribing information, so prior standard vaccination may not meet it. | FDA label |
| Or prophylaxis | If urgent therapy is indicated in a patient not up to date, give antibacterial drug prophylaxis and the vaccines as soon as possible; the REMS requires the prescriber to write the prophylaxis prescription. The label says optimal regimens and durations have not been studied. | FDA label |
| Contraindication | Do not initiate in a patient with unresolved serious Neisseria meningitidis infection. The REMS lists this assessment before treatment initiation. | FDA REMS page |
| Pneumococcal and Hib | Section 5.3 notes increased susceptibility to S. pneumoniae and H. influenzae, higher risk in children, and says to vaccinate against S. pneumoniae and Hib per ACIP; the sentence states no age limit, but it directly follows one about children, and section 17 and the Medication Guide address these vaccines for children. Not a REMS element. | FDA label |
| Book a certified site | Certified healthcare settings and pharmacies contact the REMS to verify prescriber certification before dispensing each prescription. They assess and document meningococcal vaccination status, including prophylaxis if needed, before the first dose, and for up to 6 months after it in patients not initially up to date. | FDA REMS page |
| OneSource enrollment | Online, or by email to OneSource@Alexion.com or fax to 1-800-420-5150, with the signed form. Patient and prescriber forms are separate. | OneSource enrollment |
| Biosimilars | Bkemv (eculizumab-aeeb) and Epysqli (eculizumab-aagh) labels list NMOSD in AQP4 antibody positive adults (Indications 1.4, 06/2026) at the same dosage. Each has its own REMS, the BKEMV REMS and the EPYSQLI REMS; certification in the ULTOMIRIS and SOLIRIS REMS is separate. | Bkemv label |
Prior authorization criteria and what to document
One public policy as the example: Aetna, November 10, 2026. Approval the bulletin does not state how long an approval lasts; it lists separate criteria for a first approval and for continuing treatment. This is Aetna Clinical Policy Bulletin 0807 for commercial medical plans, last reviewed on November 10, 2026, after the current Soliris label. It covers Soliris, Bkemv and Epysqli, requires precertification and applies a site of care policy. Its background text still says the 2 biosimilars lack the NMOSD use, which their June 2026 labels now include. It is here as an example of what a plan asks for, not as a rule.
| Element | What the policy asks | In the chart | Source |
|---|---|---|---|
| AQP4 serostatus | Anti-aquaporin-4 (AQP4) antibody positive | Antibody report with assay and date | Aetna policy |
| Core clinical characteristic | One of: optic neuritis, acute myelitis, area postrema syndrome, acute brainstem syndrome, symptomatic narcolepsy or acute diencephalic syndrome with NMOSD-typical diencephalic MRI lesions, symptomatic cerebral syndrome with NMOSD-typical brain lesions | Clinic note and MRI report | Aetna policy |
| Concomitant therapy | Not received concomitantly with other biologics for the treatment of NMOSD | Current NMOSD medication list | Aetna policy |
| Prescriber | Prescribed by or in consultation with a neurologist | Specialty on the request | Aetna policy |
| Continuation | No evidence of unacceptable toxicity or disease progression; positive response, for example a reduction in number of relapses; still no concomitant NMOSD biologic | Relapse history before and on treatment | Aetna policy |
| Product and site | CPB 0807 covers Soliris, Bkemv and Epysqli, requires precertification, applies the Site of Care policy for specialty drug infusions, and says commercial plans may require a lower-cost preferred drug first. No approval duration is stated. | Check the plan's preferred product list before submitting | Aetna policy |
| Biosimilar wording in the policy | The bulletin's background still says Bkemv and Epysqli carry Soliris's indications except NMOSD; the Epysqli and Bkemv labels added NMOSD in 06/2026 | Current biosimilar label if the plan steers to one | Epysqli label |
| Appeal tools | Alexion Access Navigator posts an NMOSD sample letter of medical necessity, an NMOSD sample appeal letter, a peer-to-peer review guide, a coding and billing guide, a reauthorization guide and home infusion access considerations | Payer submission packet | Alexion Access Navigator |
Soliris dosing and titration
| When | Label | Source |
|---|---|---|
| Days 1, 8, 15, 22 | 900mg IV weekly for the first 4 weeks. | FDA label |
| Day 29 | 1,200mg for the fifth dose, 1 week after the fourth. | FDA label |
| Every 2 weeks | 1,200mg every 2 weeks thereafter. The sentence allowing doses within 2 days of the scheduled time points appears in 2.2 (PNH) and after Table 1 in 2.4 (pediatric aHUS and gMG); 2.3 does not repeat it for adult NMOSD. | FDA label |
| Preparation | Dilute to 5mg/mL with an equal volume of 0.9% or 0.45% sodium chloride, 5% dextrose or Ringer's injection: 180mL final volume for 900mg, 240mL for 1,200mg. Diluted solution keeps up to 24 hours at 2 to 8°C or room temperature; allow to reach room temperature before use. | FDA label |
| Administration | IV infusion only, never push or bolus, over 35 minutes in adults by gravity feed, syringe-type pump or infusion pump. May be slowed or stopped for an adverse reaction; total infusion time should not exceed 2 hours in adults. | FDA label |
| Plasmapheresis or plasma exchange | Most recent dose 600mg or more: 600mg per session. Most recent dose 300mg: 300mg per session. Within 60 minutes after each session (Table 2). | FDA label |
| Fresh frozen plasma | Most recent dose 300mg or more: 300mg per infusion of fresh frozen plasma, 60 minutes prior to each infusion (Table 2). | FDA label |
| IVIg | Table 3 supplemental dosing is specified for patients with gMG. Sections 2.5 and 7.1 state no IVIg supplement for NMOSD. | FDA label |
| Missed dose | The Medication Guide tells the patient to call the healthcare provider right away. | FDA label |
| Vials | 300mg/30mL (10mg/mL) single-dose vial, one per carton, NDC 25682-001-01: 3 vials for 900mg, 4 for 1,200mg. Refrigerate at 2 to 8°C in the carton; one single period up to 3 days at room temperature not above 25°C is allowed. Do not freeze or shake. | FDA label |
Monitoring the Soliris label requires
| When | What | What the label says to do with it | Source |
|---|---|---|---|
| Before day 1 | Meningococcal vaccination status against the ACIP complement inhibitor schedule; unresolved meningococcal infection | Required by the label and the REMS; prophylaxis prescription if urgent | FDA REMS page |
| Each infusion | Infusion-related reactions, including anaphylaxis or other hypersensitivity reactions | Observe at least 1 hour after completion; interrupt and give supportive measures for cardiovascular instability or respiratory compromise | FDA label |
| Any time | Meningococcal infection: fever, fever and a rash, fever with high heart rate, headache with nausea or vomiting, headache and a fever, headache with a stiff neck or stiff back, confusion, muscle aches with flu-like symptoms, eyes sensitive to light | Evaluate immediately; consider interrupting Soliris during treatment of serious meningococcal infection, weighing the risk of interruption in NMOSD | FDA label |
| Per ACIP | Meningococcal revaccination | Revaccinate considering the duration of therapy; vaccination does not eliminate risk | FDA label |
| Ongoing | Other Neisseria and encapsulated bacterial infections, including disseminated gonococcal infection; Aspergillus in immunocompromised and neutropenic patients | Use caution with any other systemic infection; counsel on gonorrhea prevention and regular testing for patients at risk | FDA label |
| NMOSD trial safety | Upper respiratory tract infection 29% against 13%, nasopharyngitis 21% against 19%, diarrhea 16% against 15%, back pain 15% against 13%, dizziness 15% against 13%, influenza 11% against 4%, arthralgia 11% against 11%, pharyngitis 10% against 6%, contusion 10% against 4% | 96 on Soliris and 47 on placebo; ages 19 to 75, 91% female | FDA label |
| Adverse event reporting | Adverse events suggestive of meningococcal infection, with clinical outcomes | The REMS requires reporting to Alexion; the label lists 1-844-259-6783 | FDA REMS page |
| After stopping | Patient Safety Card carried for 3 months after the last dose; increased meningococcal risk persists for several weeks | Section 5.4 discontinuation monitoring is written for PNH (8 weeks) and aHUS (12 weeks), not NMOSD | FDA label |
Soliris drug interactions and contraindications
| Label category | Agents and what the label says | Source |
|---|---|---|
| Supplemental dose | Plasma exchange, plasmapheresis and fresh frozen plasma infusion reduce serum eculizumab and require a supplemental dose; for IVIg the label requires one in gMG | FDA label |
| Monitor | Neonatal Fc receptor (FcRn) blockers may lower systemic exposure and reduce effectiveness; closely monitor for reduced effectiveness | FDA label |
| Anticoagulants | Treatment should not alter anticoagulant management | FDA label |
| Trial background therapy | 76% of patients in the NMOSD trial received concomitant immunosuppressive therapy, including chronic corticosteroids; rituximab or mitoxantrone within 3 months and IVIg within 3 weeks before screening were exclusions | FDA label |
| Pregnancy and lactation | Limited data from more than 300 pregnancies with live births have not suggested safety concerns but cannot exclude risk; data are insufficient on effects on the breastfed infant. The label lists no pregnancy registry. | FDA label |
Why a first fill stalls, and the fix
- Your vaccine dates are missingThe REMS has certified sites check and record your meningococcal vaccine status before the first dose. The fix is the office sending the vaccine dates, or the antibiotic prescription if treatment cannot wait.
- The infusion site is not certifiedOnly healthcare settings and pharmacies certified in the ULTOMIRIS and SOLIRIS REMS may dispense it. The office moves the booking to a certified site, which makes it a routing problem rather than a denial.
- The AQP4 antibody result or the specialist is missingThe Aetna policy below asks for a positive AQP4 antibody test. It also asks for at least one core clinical feature of NMOSD, such as optic neuritis or acute myelitis. It also asks that a neurologist prescribe Soliris or be consulted. Your neurologist's office sends the lab report and clinic notes.
- Another NMOSD biologic is on your recordThe Aetna policy says Soliris will not be given at the same time as other biologics for NMOSD. Your neurologist's office lists your current NMOSD treatments in the request it sends.
- Your plan prefers a different eculizumab productThe Aetna policy covers Soliris, Bkemv and Epysqli. It says Aetna commercial plans may require a trial of a lower-cost preferred drug before a higher-cost one in the same class.
- A denial your neurologist wants to appealAlexion Access Navigator posts an NMOSD sample letter of medical necessity and a sample appeal letter for doctors' offices. It also posts a guide to peer-to-peer review, a step before a formal appeal.
- A copay you cannot payWith commercial insurance, the OneSource CoPay Program can bring the cost as low as $0 and may help with some infusion costs. Medicare, Medicaid and other government plans are excluded, and OneSource says it can connect those patients with third-party resources.
- The vaccines themselves cost moneyOneSource says it may help you find a vaccination site and share resources that may cover vaccine costs. You need to be enrolled and have the vaccines prescribed.
Alexion OneSource
- Specialists who help you make sense of your health insurance coverage, answer questions about treatment with Soliris and connect you to community resources OneSource overview
- Vaccination support for enrolled patients, including help finding a vaccination site and information on resources that may cover vaccine costs OneSource vaccines
- The Alexion OneSource CoPay Program for commercial insurance, as little as $0 for Soliris, which may also help with some infusion costs
- CoPay help is not open to Medicare, Medicaid or other federal- or state-funded plans, and OneSource can point those patients to third-party resources
- Residents of Massachusetts and Rhode Island can get help with medicine costs but not infusion costs, and annual maximums may apply, under the CoPay terms CoPay terms
- Enrollment online, by email to OneSource@Alexion.com or by fax at 1-800-420-5150, with interpreters available OneSource enrollment
Questions prescribers' offices ask about Soliris
What is the Soliris dose for NMOSD?
900mg IV weekly for the first 4 weeks, 1,200mg for the fifth dose 1 week later, then 1,200mg every 2 weeks, per section 2.3 of the label revised June 2026. The adult dose is fixed, not weight-based. Infuse over 35 minutes, do not exceed 2 hours if slowed, and observe for at least 1 hour after completion.
Which vaccines are required before Soliris?
Meningococcal vaccines against serogroups A, C, W, Y and B, completed or updated at least 2 weeks before the first dose, per the boxed warning and section 2.1 of the label revised June 2026, on the ACIP schedule for complement inhibitor recipients. Section 5.3 notes higher pediatric risk and says to vaccinate against Streptococcus pneumoniae and Hib per ACIP, a sentence that states no age limit but directly follows one about children, and section 17 and the Medication Guide address these vaccines for children; the REMS covers meningococcal status only.
Can Soliris start before the vaccines have had 2 weeks?
Yes, if urgent therapy is indicated and the patient is not up to date 2 weeks before the first dose, the label revised June 2026 says to give antibacterial drug prophylaxis and meningococcal vaccines as soon as possible. The REMS requires the prescriber to write that prescription, and the label notes that optimal prophylaxis regimens and durations have not been studied.
What supplemental Soliris dose follows plasma exchange in NMOSD?
600mg within 60 minutes after each plasmapheresis or plasma exchange session when the most recent dose was 600mg or more, and 300mg when it was 300mg, per Table 2 of the label revised June 2026. Fresh frozen plasma takes 300mg given 60 minutes before each infusion. The IVIg table (Table 3) is written for gMG; the label states no IVIg supplement for NMOSD.
What do insurers ask for to approve Soliris for NMOSD?
One example, Aetna CPB 0807, last reviewed November 10, 2026, asks for AQP4 antibody positivity, at least one of 6 core clinical characteristics of NMOSD, no concomitant biologic for NMOSD, and a neurologist prescribing or consulted. Continuation needs no unacceptable toxicity or progression and a positive response such as fewer relapses. The bulletin states no approval duration and covers Soliris, Bkemv and Epysqli.
Free email alert
Get an email when the Soliris label changes
One email the day the FDA revises the Soliris prescribing information, with a summary of what changed. No trial alerts or newsletter, and you can stop anytime.
Label changes for Soliris only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Sources
- SOLIRIS (eculizumab) injection, for intravenous use, prescribing information and Medication Guide, SPL version 44, label revised 06/2026, Medication Guide revised 02/2025, Alexion Pharmaceuticals, via openFDA, 2026-07-08.
- Approved Risk Evaluation and Mitigation Strategies (REMS): Ultomiris and Soliris (eculizumab), BLA 125166 and BLA 761108, REMS last update 06/01/2026, FDA, 2026-06-01.
- Alexion OneSource™ | SOLIRIS | Financial Assistance, Alexion Pharmaceuticals, 2026-11-12.
- Alexion OneSource™ CoPay Program Terms and Conditions, US/ALL/1223 V1 12/2024, Alexion Pharmaceuticals, 2026-11-12.
- Alexion OneSource™ | SOLIRIS | About OneSource™, Alexion Pharmaceuticals, 2026-11-12.
- Alexion OneSource™ | SOLIRIS | Fill Out a Start Form, Alexion Pharmaceuticals, 2026-11-12.
- Alexion OneSource™ | SOLIRIS | Vaccination Support, Alexion Pharmaceuticals, 2026-11-12.
- Alexion Access Navigator | Soliris NMOSD, Alexion Pharmaceuticals, 2026-11-12.
- Eculizumab - Medical Clinical Policy Bulletins | Aetna, Number 0807, Aetna, 2026-11-10.
- BKEMV (eculizumab-aeeb) label, SPL version 8, Indications and Usage (1.4) changed 06/2026, Amgen, via openFDA, 2026-07-02.
- EPYSQLI (eculizumab-aagh) label, SPL version 5, Indications and Usage (1.4) changed 06/2026, Teva Pharmaceuticals USA, via openFDA, 2026-07-06.
- BLA 761108/S-046 and BLA 125166/S-455 accelerated approval letter, Ultomiris IgA nephropathy and REMS modification, FDA, 2026-10-21.
- BLA 125166/S-454 supplement approval letter, Soliris labeling, FDA, 2026-06-30.
- BLA 125166/S-448 and BLA 761108/S-038 supplement approval letter, Soliris pediatric gMG and REMS modification, FDA, 2025-02-28.
- BLA 125166/S-443 supplement approval letter, combined REMS with Ultomiris, FDA, 2024-03-22.
- BLA 125166/S-431 supplement approval letter, Soliris for NMOSD, FDA, 2019-06-27.
A reference drawn from the July 8, 2026 label, the drugmaker's published program and one public insurer policy shown as an example, checked on November 12, 2026. Labels and policies change; the label on DailyMed and the plan's current policy govern. Trial Friend is not a medical provider. It reports what these documents say and does not judge whether a drug is safe or right for any patient; that is the prescriber's decision. Not a substitute for the prescribing information.